Breaking News Headlines Today

News from psychedelicalpha.com

See all of psychedelicalpha.com news coverage in one place. Discover how psychedelicalpha.com’s media bias informs their coverage and compare with thousands of other news outlets.

In total, 29 have been published by psychedelicalpha.com which Ground News has aggregated in the past 3 months.

We’ve assigned a media bias rating of unknown to psychedelicalpha.com. You can read more about our methodology here.

If you want to know if psychedelicalpha.com is credible or reliable, look no further. We rank psychedelicalpha.com as Unknown factuality. Find out more about our methodology here.

Information about psychedelicalpha.com

Where is psychedelicalpha.com located?psychedelicalpha.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top psychedelicalpha.com News

FDA · United States

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect - Psychedelic Alpha

Last August, Lykos Therapeutics announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) to its new drug application (NDA) that sought to have MDMA-assisted therapy approved for PTSD. In real terms, the agency had rejected Lykos’ first shot at getting the drug approved. After a period of intense reporting last year, we shifted focus to what the future… Source See the Story

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research - Psychedelic Alpha

One of the things that made the recent Neurobiology of Psychedelics Gordon Research Conference (GRC) special was that it provided a venue for junior scientists to interact with pioneers of the field. With such a small attendee list and a one-track scientific agenda, conference-goers were able to network and learn directly from the best of the best.One of those pioneers is Dr. Mark Geyer… Source Read Article

United Kingdom · United Kingdom

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions - Psychedelic Alpha

Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as filings are not required immediately at the end of each quarter. Here’s a review of Q2 2025 activity… Psychedelic drug developers’ spend on federal lobbying in Q2’25 looked very similar to that seen in the first quarter… Source Read Article

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches - Psychedelic Alpha

Ketamine-assisted therapy (KAT) shows remarkable promise as a breakthrough psychiatric treatment for severe alcohol addiction, but recreational use of the dissociative is spiralling out of control. Professor Celia Morgan from the University of Exeter, who has led the world’s largest studies of KAT, discusses both the potential and pitfalls of the drug and whether calls for the UK Government to… SourceExeter, England · Exeter Read Article

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling? - Psychedelic Alpha

AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Draft Depression Guideline • National Survey Reveals Psychedelics Use Again Rises in US • FDA Moves to Ban Kratom Compound 7-OH • Compass Talks Accelerated Approval on Q2’25 Earnings Call • atai All-In on Psychedelics Following RL-007 Flop • UK Governm…Kyrsten Sinema · United States Read Article

Filament Health Receives First-Ever Approval for Compassionate Use of Psilocybin in the EU

The Marijuana Herald - Marijuana news and information In a historic move for psychedelic medicine, Germany has granted the first-ever compassionate use approval for psilocybin in the European Union. The authorization allows a patient with treatment-resistant depression to receive Filament Health’s botanical psilocybin drug candidate, PEX010, outside of a clinical trial setting. The treatment will be administered by Dr. Gerhard Gründer at the Ce…Psychedelics · Germany See the Story

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) - Psychedelic Alpha

In her first Dispatch, Dr. Alaina Jaster covered the inaugural Neurobiology of Psychedelics Gordon Research Conference’s Keynote Sessio,n plus the first day of the gathering. Here, she covers the remainder: days 2, 3, and 4.Editor’s note: GRC has a strict publication policy; thus, the presenters referenced here provided consent for publication. Some of the speakers either did not consent or were… SourceConsciousness Read Article

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research - Psychedelic Alpha

FDA Keeps GH Research’s 5-MeO-DMT on Ice as atai and Beckley Surge Ahead • Makary’s Priority Voucher Program Launches, Cites Novel PTSD Treatment as Example • HALT Fentanyl Act Signed by Trump, Could Streamline Schedule I Researcher Registration • Czech President Signs Medical Psilocybin Into Law • Psychedelic Stocks Surge, Compass Recovers from Readout Sell-off • New Zealand’s Regulator Publishes Psychedelics Prescribing GuidanceCzechia · Czechia Read Article

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1) - Psychedelic Alpha

The inaugural Neurobiology of Psychedelics Gordon Research Conference took place July 12th to 18th on the quiet campus of Bryant University in Smithfield, Rhode Island. The conference, also referred to as the ‘Psychedelic GRC’, was an international meeting focused on advancing science through the presentation of research, lively discussion and fostering a sense of camaraderie and community among… SourceSmithfield, Rhode Island · Smithfield Read Article

CCHR Cautions Veterans: Psychedelics Reflect a Dark History of Exploitation, Harm and Failed Science

67% Left coverage: 9 sources

LOS ANGELES, Calif., July 14, 2025 (SEND2PRESS NEWSWIRE) — The Citizens Commission on Human Rights International (CCHR) is warning Congress and the public that new legislation to legalize psychedelic drugs for U.S. veterans is a dangerous repeat of history—when defenders…Psychedelics · Los Angeles See the Story

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook - Psychedelic Alpha

On Wednesday afternoon at Psychedelic Science I (Psychedelic Alpha Editor Josh Hardman) sat down with former U.S. Senator Kyrsten Sinema for a conversation about her vocal advocacy for ibogaine. We sat at the booth of Tijuana-based ibogaine clinic Ambio Life Sciences in the bustling Expo Hall. Sinema’s style was just as eccentric as her political background, with a bright outfit and translucent… SourceKyrsten Sinema · Tijuana Read Article

News from psychedelicalpha.com